New Drugs Coming Down the
Pike
by Glen Pietrandoni, R.Ph.
Once upon a time
the
alarm clock had to be set every few hours, 24/7, as a reminder
to take a dose of AZT. You got through it. Then came combination
therapies, 12 pills at a time, three times a day, with food,
plus a few others on an empty stomach a couple of hours later.
You got through it. Then came along Crixivan every 8 hours
or chewable Videx twice a day. Once again you got through
it. Norvir liquid, enough said. At last, there is some good
news. Once daily dosing is here for some drug products and
just around the corner are quite a few more drugs.
Ideally, drugs that can be
dosed once a day must be very potent, have minimal side effects,
and should be forgiving for late or missed doses.
In order to allow prescription drugs to be brought to market
quicker, pharmaceutical companies file for Food and Drug Administra-tion
(FDA) approval before dosing studies are finished. Once the
drugs are on the market, they are still being studied in order
to get approval for easier dosing. In some situations, clinicians
can use pharmacokinetic (PK) data to make educated adjustments
in dose and will prescribe drugs with off label
directions. Basically, PK data tells us how much drug is in
the blood and for how long. Blood levels need to be above
a minimum level to be effective, but not too high as to cause
toxic effects.
For example, because blood
levels remain high for Viracept, it is now approved for twice
daily dosing (5 tablets twice daily, instead of 3 tablets
three times daily). Other times, the FDA rejects changes to
originally approved dosing regimens, as in the case of Crixivan.
Twice daily dosing of Crixivan did not show high enough levels
of drug and the virus became resistant to the drug. Unless
used in combination with other protease inhibitors, Crixivan
is only approved for dosing every 8 hours, and never twice
daily.
Before you get too excited
about the possibility of leaving all your medicine at home
and feeling free of the ball and chain, there are a few things
you must know. If daily dosing were available, then each daily
dose of the drug would become even more important. With adherence
needing to be above the 95% level, even two missed doses per
month could put you at risk for viral resistance and drug
failure. It may also be important to be consistent with the
time of the dose from day to day. The window for taking medication
may not be much more flexible than 24 hours so drugs must
be taken at the same time every day. The studies being conducted
on once-a-day dosing regimens will address these issues, so
dont try this at home. Only your doctor can change the
way to take your prescription drugs.
As mentioned, there
is a large effort by the pharmaceutical companies to make
taking the drug cocktails easier for people to handle. It
has been shown that a simple regimen is easier to take and
is effective for a longer period of time than more complex
drug therapies. (Duh). But until once a day dosing is available,
youll get through it.
Glen Pietrandoni is director
of Clinical Pharmacy Services for the HIV-specialty Walgreens
pharmacy located in the Howard Brown Health Center of Chicago.
Once-daily drugs
available now
|
|
Sustiva
|
600 mg once daily approved;
single 600 mg tablet soon
|
|
Videx (ddI)
|
400 mg once daily approved;
400 mg enteric coated tablet soon
|
|
Viramune
|
400 mg once daily being
studied
|
|
Epivir (3TC)
|
300 mg once daily being
studied
|
|
Crixivan/Norvir
|
1000 mg/100 mg or 1000
mg/200 mg once daily being studied
|
|
Fortovase/Norvir
|
1600 mg/100 mg once
daily being studied
|
Once-daily drugs in research
|
Coviracil (FTC)
|
once daily nucleoside
similar to 3TC
|
Lodanosine (F-dda)
|
once daily nucleoside
similar to ddI
|
DOTC (BCH)
|
once daily nucleoside
similar to 3TC
|
GW420867X
|
once daily nucleoside
|
Adefovir
|
once daily nucleotide,
will not be available in the US
|
Tenofovir
(bis-POC PMPA)
|
once daily nucleotide,
limited expanded access in the US
|
DPC 961 and DPC
963
|
once daily non-nucleoside.
Phase III studies for DPC 961
|
PNU142721
|
one or two times daily
non-nucleoside, related to delavirdine
|
BMS 232632
|
one or two times daily
protease inhibitor, phase I/II
|
L-756,424
|
one or two times daily
protease inhibitor, will be dosed with indinavir 1600
mg/800 mg once daily, or 800 mg/400 mg twice daily
|
T-1249
|
once daily second generation
fusion inhibitor (sub-Q injection)
|
|